We're taking a closer look at Viking Therapeutics today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved 7.6% compared to 0.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:
-
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
-
Viking Therapeutics has moved 218.8% over the last year compared to 25.5% for the S&P 500 -- a difference of 193.3%
-
VKTX has an average analyst rating of buy and is -51.6% away from its mean target price of $113.36 per share
-
Its trailing 12 month earnings per share (EPS) is $-0.92
-
Viking Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of -59.6 while the S&P 500 average is 27.65
-
Its forward earnings per share (EPS) is $-1.54 and its forward P/E ratio is -35.6
-
VKTX has a Price to Earnings Growth (PEG) ratio of -1.13, which shows the company is fairly valued compared to its earnings.
-
The company has a Price to Book (P/B) ratio of 6.48 in contrast to the S&P 500's average ratio of 4.59
-
Viking Therapeutics is part of the Health Care sector, which has an average P/E ratio of 27.53 and an average P/B of 3.61
-
Viking Therapeutics has on average reported free cash flows of $-39107166.7 over the last four years, during which time they have grown by an an average of -27.5%